Full Federal Circuit to rule on inequitable conduct

01 June 2010

A full panel of the Federal Circuit has agreed to re-hear a case regarding the US doctrine of inequitable conduct, answering Chief Judge Paul Michel's plea to IP practitioners last year

by Eileen McDermott, New York

Chief Judge Michel and the Federal Circuit

At the AIPLA Annual Meeting in Washington DC last October, Michel appealed to attendees to help clarify the doctrine of inequitable conduct by bringing cases that raise the subject before the court. "We can't develop issues unless you raise them," said Michel.

In late April, Therasense (now Abbott Laboratories) did just that, when its petition for an en banc rehearing of the court's January ruling in favour of Becton Dickinson and Company and Nova Biomedical was granted by the court.

The district court found one of the patents at issue in the case – US patent number 5,820,551 – unenforceable for inequitable conduct due to a failure to disclose statements made to the EPO, and the Federal...



Only subscribers have complete access to Managing IP Magazine, log in or subscribe now.

Alternatively take a free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).

Subscribe Now

This article is available to subscribers. Please click subscribe to read the rest of the article.

Subscribe

Take a free trial

Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.

Take a free trial


INTA Daily News 2012

Read this year's INTA Daily News - published daily by Managing IP direct from the 134th INTA Annual Meeting in Washington DC

null null null
null null

May 2012

Do you want to be famous?

Famous, well-known, notorious, reputed: everyone wants enhanced protection for their trade marks. But should they, and what does it mean if it is? Emma Barraclough explains



Most read articles

Poll

Will the new post grant and inter partes review proceedings result in more litigators practising pro hac vice before the USPTO?







Supplements